Selective FP Receptor Agonist for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma treatments lack sufficient intraocular pressure lowering action with minimal side effects, as existing prostaglandin derivatives often exhibit agonistic activity on IP, EP2, and EP4 receptors, leading to potential eye-stimulating properties and inflammatory responses.
Innovation Solution
Development of a compound with selective agonistic activity on the FP receptor, reducing agonistic activity on IP and EP2/EP4 receptors, thereby providing strong intraocular pressure lowering action without eye-stimulating side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing prostaglandin derivatives (PGF and PGI) are used to lower intraocular pressure, then intraocular pressure lowering action is achieved, but side effects such as eye stimulation and hyperemia occur due to agonistic activity on IP, EP2, and EP4 receptors
Solution Approach 1:
The patent applies local quality by creating selective receptor agonism - the compound structure is designed to specifically activate FP receptors while avoiding activation of IP, EP2, and EP4 receptors. This selective activity profile localizes the beneficial effect to the desired target while avoiding harmful effects at other receptor sites, thereby reducing eye-stimulating side effects while maintaining intraocular pressure lowering action
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of prostaglandin derivatives to alter receptor binding characteristics. Through structural optimization, the compound achieves high affinity for FP receptors while maintaining low affinity for other prostaglandin receptors, thereby changing the overall receptor activation profile to eliminate harmful side effects while preserving therapeutic efficacy
2Reliability
If high concentration administration or joint use of drugs with different mechanisms is performed to strengthen intraocular pressure lowering action, then stronger intraocular pressure lowering action is achieved, but manifestation of side effects is feared
Solution Approach 1:
The patent uses parameter changes to optimize the therapeutic index by modifying the pharmacological properties of the compound through structural optimization. The resulting compound achieves high efficacy at low concentrations through selective FP receptor activation, eliminating the need for high concentration administration or combination therapy while minimizing side effects
Data Source
Figure 1~2
AI summary
Provided is a compound which has strong intraocular pressure lowering action and has no side effect on eyes such as ocular stimulating property, humor protein rise etc. Since a compound represented by the formula (I): (wherein definition of each group is as described in the specification), or a salt thereof, a solvate thereof, or a prodrug thereof has strong intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.